|
1
|
Sanderson RJ and Ironside JA: Squamous
cell carcinomas of the head and neck. BMJ. 325:822–827. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rezende TM, de Souza Freire M and Franco
OL: Head and neck cancer: Proteomic advances and biomarker
achievements. Cancer. 116:4914–4925. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chi AC, Day TA and Neville BW: Oral cavity
and oropharyngeal squamous cell carcinoma-an update. CA Cancer J
Clin. 65:401–421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP
and Morris LG: Decision making in the management of recurrent head
and neck cancer. Head Neck. 36:144–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garavello W, Ciardo A, Spreafico R and
Gaini RM: Risk factors for distant metastases in head and neck
squamous cell carcinoma. Arch Otolaryngol Head Neck Surg.
132:762–766. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Walsh JE, Lathers DM, Chi AC, Gillespie
MB, Day TA and Young MRl: mechanisms of tumor growth and metastasis
in head and neck squamous cell carcinoma. Curr Treat Options Oncol.
8:227–238. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jung AC, Ray AM, Ramolu L, Macabre C,
Simon F, Noulet F, Blandin AF, Renner G, Lehmann M, Choulier L, et
al: Caveolin-1-negative head and neck squamous cell carcinoma
primary tumors display increased epithelial to mesenchymal
transition and prometastatic properties. Oncotarget. 6:41884–41901.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferlito A, Shaha AR, Silver CE, Rinaldo A
and Mondin V: Incidence and sites of distant metastases from head
and neck cancer. ORL J Otorhinolaryngol Relat Spec. 63:202–207.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merlano M, Vitale V, Rosso R, Benasso M,
Corvò R, Cavallari M, Sanguineti G, Bacigalupo A, Badellino F,
Margarino G, et al: Treatment of advanced squamous-cell carcinoma
of the head and neck with alternating chemotherapy and
radiotherapy. N Eng J Med. 327:1115–1121. 1992. View Article : Google Scholar
|
|
11
|
Molinolo AA, Amornphimoltham P, Squarize
CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular
networks in head and neck carcinogenesis. Oral Oncol. 45:324–334.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi P and Chen C: Genetic expression
profiles and biologic pathway alterations in head and neck squamous
cell carcinoma. Cancer. 104:1113–1128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koshizuka K, Hanazawa T, Fukumoto I,
Kikkawa N, Okamoto Y and Seki N: The microRNA signatures:
Aberrantly expressed microRNAs in head and neck squamous cell
carcinoma. J Hum Genet. 62:3–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hedberg ML, Goh G, Chiosea SI, Bauman JE,
Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, et
al: Genetic landscape of metastatic and recurrent head and neck
squamous cell carcinoma. J Clin Invest. 126:169–180. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gaykalova DA, Mambo E, Choudhary A,
Houghton J, Buddavarapu K, Sanford T, Darden W, Adai A, Hadd A,
Latham G, et al: Novel insight into mutational landscape of head
and neck squamous cell carcinoma. PLoS One. 9:e931022014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Diepenbruck M and Christofori G:
Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no,
maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Heldin CH, Vanlandewijck M and Moustakas
A: Regulation of EMT by TGFβ in cancer. FEBS Lett. 586:1959–1970.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zavadil J and Böttinger EP: TGF-beta and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zavadil J, Cermak L, Soto-Nieves N and
Böttinger EP: Integration of TGF-beta/Smad and Jagged1/Notch
signalling in epithelial-to-mesenchymal transition. EMBO J.
23:1155–1165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moreno-Caceres J, Caja L, Mainez J,
Mayoral R, Martín-Sanz P, Moreno-Vicente R, Del Pozo MÁ, Dooley S,
Egea G and Fabregat I: Caveolin-1 is required for TGF-β-induced
transactivation of the EGF receptor pathway in hepatocytes through
the activation of the metalloprotease TACE/ADAM17. Cell Death Dis.
5:e13262014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fridolfsson HN, Roth DM, Insel PA and
Patel HH: Regulation of intracellular signaling and function by
caveolin. FASEB J. 28:3823–3831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Del Galdo F, Lisanti MP and Jimenez SA:
Caveolin-1, transforming growth factor-beta receptor
internalization, and the pathogenesis of systemic sclerosis. Curr
Opin Rheumatol. 20:713–719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sloan EK, Stanley KL and Anderson RL:
Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene.
23:7893–7897. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chatterjee M, Ben-Josef E, Thomas DG,
Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA,
Chen CS, Ludwig T, et al: Caveolin-1 is associated with tumor
progression and confers a multi-modality resistance phenotype in
pancreatic cancer. Sci Rep. 5:108672015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sugie S, Mukai S, Yamasaki K, Kamibeppu T,
Tsukino H and Kamoto T: Significant association of caveolin-1 and
caveolin-2 with prostate cancer progression. Cancer Genomics
Proteomics. 12:391–396. 2015.PubMed/NCBI
|
|
30
|
Zhang H, Su L, Müller S, Tighiouart M, Xu
Z, Zhang X, Shin HJ, Hunt J, Sun SY, Shin DM and Chen ZG:
Restoration of caveolin-1 expression suppresses growth and
metastasis of head and neck squamous cell carcinoma. Br J Cancer.
99:1684–1694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sacks PG: Cell, tissue and organ culture
as in vitro models to study the biology of squamous cell carcinomas
of the head and neck. Cancer Metastasis Rev. 15:27–51. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transition in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moreno-Bueno G, Peinado H, Molina P,
Olmeda D, Cubillo E, Santos V, Palacios J, Portillo F and Cano A:
The morphological and molecular features of the
epithelial-to-mesenchymal transition. Nat Protoc. 4:1591–1613.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu C, Liu Y, Huang D, Dai Y, Cai G, Sun J,
Xu T, Tian Y and Zhang X: TGF-β1 mediates epithelial to mesenchymal
transition via the TGF-β/Smad pathway in squamous cell carcinoma of
the head and neck. Oncol Rep. 25:1581–1587. 2011.PubMed/NCBI
|
|
36
|
Pi LM, Liu Y, Yu CY, Cai GM, Hunag DH, Qiu
YZ, Tian YQ and Zhang X: EGCG regulates TGF-β1-induced epithelial
mesenchymal transition in squamous cell carcinoma of head and neck.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 47:749–752. 2012.(In
Chinese). PubMed/NCBI
|
|
37
|
Lu Z, Ghosh S, Wang Z and Hunter T:
Downregulation of caveolin-1 function by EGF leads to the loss of
E-cadherin, increased transcriptional activity of beta-catenin, and
enhanced tumor cell invasion. Cancer Cell. 4:499–515. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bailey KM and Liu J: Caveolin-1
up-regulation during epithelial to mesenchymal transition is
mediated by focal adhesion kinase. J Biol Chem. 283:13714–13724.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miyazono K: Transforming growth
factor-beta signaling in epithelial-mesenchymal transition and
progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci.
85:314–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Papageorgis P, Lambert AW, Ozturk S, Gao
F, Pan H, Manne U, Alekseyev YO, Thiagalingam A, Abdolmaleky HM,
Lenburg M and Thiagalingam S: Smad signaling is required to
maintain epigenetic silencing during breast cancer progression.
Cancer Res. 70:968–978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Araki S, Eitel JA, Batuello CN,
Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman
DA and Mayo LD: TGF-beta1-induced expression of human Mdm2
correlates with late-stage metastatic breast cancer. J Clin Invest.
120:290–302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schwartz EA, Reaven E, Topper JN and Tsao
PS: Transforming growth factor-beta receptors localize to caveolae
and regulate endothelial nitric oxide synthase in normal human
endothelial cells. Biochem J. 390:199–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
